Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to ...

We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...

It follows a similar lawsuit against Pfizer and BioNTech filed in April in which GSK alleges the companies were in violation ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal ...

春日融融启新篇，药界盛会邀群贤。 2025年3月1日至3月2日， IBI EXPO 2025（第三届）生物创新药产业大会将在 苏州国际博览中心盛大举办。 大会聚焦 ...

A new study has provided a detailed analysis of how mRNA vaccines circulate and break down in the human bloodstream. The research aimed to help improve the safety and effectiveness of these vaccines, ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

作者：黄莺俗话说人红是非多。在新冠疫情期间，凭借mRNA疫苗大获成功的Moderna公司，从年营收只有几千万美元的公司，一举跨入年营收200亿美元的公司行列。而这为其也带来了越来越多的专利纠纷。2021年，Moderna与美国国立卫生研究院的mRNA ...

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent ...

日前，曾经的mRNA疫苗明星公司斯微（上海）生物科技股份有限公司（下称“斯微生物”），被裁定进入破产程序。公开文件显示，上海市浦东新区人民法院发布公告称，本院据债权人申请于9月20日裁定受理斯微生物破产清算一案，并于2024年9月24日，指定北京金诚同达（上海）律师事务所为斯微生物管理人。

因诺纬克生物自主研发的个性化新抗原mRNA肿瘤疫苗InnoPCV是一款靶向特异性肿瘤新抗原的个性化mRNA肿瘤疫苗。通过对患者肿瘤组织和正常细胞进行深度测序，并将测序结果通过因诺纬克生物独有的生物信息预测系统InnoBINF进行分析，筛选出患者特异性 ...